Dementia and Geriatric Cognitive Disorders

Original Research Article

Asymmetrical Dimethylarginine Is Increased in Plasma and Decreased in Cerebrospinal Fluid of Patients with Alzheimer’s Disease

Arlt S.a · Schulze F.b · Eichenlaub M.a · Maas R.b · Lehmbeck J.T.a · Schwedhelm E.b · Jahn H.a · Böger R.H.b

Author affiliations

aDepartment of Psychiatry and Psychotherapy, and bInstitute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Keywords: Asymmetrical dimethylarginineCerebrospinal fluidAlzheimer’s disease

Related Articles for ""
Dement Geriatr Cogn Disord 2008;26:58–64
https://doi.org/10.1159/000144026

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Accepted: May 05, 2008
Published online: July 10, 2008
Issue release date: July 2008

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Abstract

Background: Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase and may alter NO production during pathological conditions. Concerning Alzheimer’s disease (AD), there are reports on altered cerebral NO metabolism, but only few studies on ADMA concentrations in plasma and cerebrospinal fluid (CSF). Methods: We assessed plasma ADMA in 80 AD patients and 80 age- and gender-matched controls and CSF ADMA in a subgroup of 53 AD patients and 20 controls. Results: ADMA plasma concentrations were increased, while CSF ADMA concentrations were decreased in AD patients. There was a significant association between decreasing CSF ADMA levels and the severity of cognitive impairment. Conclusion: Elevated ADMA in plasma might be a contributing factor for AD through alterations of NO metabolism, for example decreased cerebral microperfusion, while decreased levels of CSF ADMA might lead to a cerebral increase of NO, peroxynitrite production and oxidative protein damage. Our study reveals different mechanisms of plasma and CSF ADMA regulation, both potentially contributing to AD pathology.

© 2008 S. Karger AG, Basel



Related Articles:

References

  1. Hawkins RD: No honey, I don’t remember. Neuron 1996;16:465–467.
    External Resources
  2. Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113:1708–1714.
    External Resources
  3. Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, Van Nostrand WE, Weinberg JB, Dawson H: NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2006;103:12867–12872.
    External Resources
  4. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572–575.
    External Resources
  5. Nakajima T, Matsuoka Y, Kakimoto Y: Isolation and identification of N-G-monomethyl, N-G, N-G-dimethyl- and N-G,N′ G-dimethylarginine from the hydrolysate of proteins of bovine brain. Biochim Biophys Acta 1971;230:212–222.
    External Resources
  6. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172–177.
    External Resources
  7. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C: Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005;46:518–523.
    External Resources
  8. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Strodter D, Simon BC, Mugge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Boger RH: Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter coronary artery risk determination investigating the influence of ADMA concentration (CARDIAC) study. Am Heart J 2006;152:493.e1–493.e8.
    External Resources
  9. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842–1847.
    External Resources
  10. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201–1203.
    External Resources
  11. Teerlink T: Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005;43:1130–1138.
    External Resources
  12. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113–2117.
    External Resources
  13. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Munzel T: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the atherogene study. Circ Res 2005;97:e53–e59.
    External Resources
  14. Maas R, Schulze F, Baumert J, Lowel H, Hamraz K, Schwedhelm E, Koenig W, Boger RH: Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based monitoring of trends and determinants in cardiovascular disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 2007;53:693–701.
    External Resources
  15. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Boger SM: ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006;37:2024–2029.
    External Resources
  16. Wanby P, Teerlink T, Brudin L, Brattstrom L, Nilsson I, Palmqvist P, Carlsson M: Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006;185:271–277.
    External Resources
  17. Selley ML: Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease. Neurobiol Aging 2003;24:903–907.
    External Resources
  18. Abe T, Tohgi H, Murata T, Isobe C, Sato C: Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer’s disease. Neurosci Lett 2001;312:177–179.
    External Resources
  19. Mulder C, Wahlund LO, Blomberg M, de Jong S, van Kamp GJ, Scheltens P, Teerlink T: Alzheimer’s disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. J Neural Transm 2002;109:1203–1208.
    External Resources
  20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
    External Resources
  21. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
    External Resources
  22. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Boger RH: Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377–1383.
    External Resources
  23. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Boger RH: Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005;35:622–626.
    External Resources
  24. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Boger RH: Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005;51:1268–1271.
    External Resources
  25. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Boger RH: High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007;851:211–219.
    External Resources
  26. Gorelick PB: Risk factors for vascular dementia and Alzheimer disease. Stroke 2004;35:2620–2622.
    External Resources
  27. Borroni B, Akkawi N, Martini G, Colciaghi F, Prometti P, Rozzini L, Di Luca M, Lenzi GL, Romanelli G, Caimi L, Padovani A: Microvascular damage and platelet abnormalities in early Alzheimer’s disease. J Neurol Sci 2002;203–204:189–193.
  28. Boger RH: Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126–136.
    External Resources
  29. Park SH, Lee HW, Kim S, Paik WK: A peptide inhibitor for S-adenosyl-L-methionine-dependent transmethylation reactions. Purification and characterization. Int J Biochem 1993;25:1157–1164.
    External Resources
  30. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343:209–214.
    External Resources
  31. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH: Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096–1098.
    External Resources
  32. Morrison LD, Smith DD, Kish SJ: Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J Neurochem 1996;67:1328–1331.
    External Resources
  33. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G: Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 1997;17:2653–2657.
    External Resources
  34. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H: Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235–239.
    External Resources
  35. Selley ML, Close DR, Stern SE: The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer’s disease. Neurobiol Aging 2002;23:383–388.
    External Resources
  36. de la Torre JC: Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152–1162.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Accepted: May 05, 2008
Published online: July 10, 2008
Issue release date: July 2008

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2008, Vol.26, No. 1

July 2008

Article

Recommend This
TOP